Lupin Reports 6.7% Net Profit Growth, Achieving Eighth Consecutive Quarter of Gains

Lupin, a prominent player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation adjustment reflecting its strong financial metrics and market position. The company reported a notable growth in net profit of 6.7% for the quarter ending September 2024, marking its eighth consecutive quarter of positive results. This consistent performance is underscored by a robust operating cash flow, which reached its highest level at Rs 3,648.36 crore.
Lupin's ability to manage debt is highlighted by a low Debt to EBITDA ratio of 0.70 times, indicating a strong capacity to service its obligations. Additionally, the company boasts a return on capital employed (ROCE) of 18.68%, further emphasizing its operational efficiency. The stock's technical indicators suggest a mildly bullish trend, with the MACD showing positive momentum since January 2025.

With a return of 36.78% over the past year, Lupin has outperformed the broader market, which recorded returns of 8.47% in the same period. The stock's attractive valuation, characterized by a price-to-book ratio of 6 and a return on equity (ROE) of 16.8%, positions it favorably within the market landscape.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.